Drugs for Parkinson's Disease Flashcards
- Akinesia
2. Bradykinesia
- Difficulty initiating movement
2. Slowness of movement
3 general ways to treat Parkinsons
- Drugs that increase DA levels in the brain
- DA receptor agonists
- Acetylcholine Antagonists
Drugs that increase DA levels
Levodopa (L-DOPA)
Precursor of DA
Can cross the BBB (unlike DA) and is taken up by neurons in the substantia nigra (where it is converted to DA by DDC)
Adverse effects: nausea, orthostatic hypotension, cardiac arrhythmias - due to increase catecholamines in peripheral tissues
Dopa decarboxylase Inhibitor
Ex: Carbidopa Analog of L-DOPA Inhibits conversion of L-DOPA to DA in peripheral tissue Does NOT cross the BBB Need combo with L-DOPA
Catechol-O-methyltransferase (COMT) inhibitors
Ex: Entacapone, tolcapone
Block conversion of L-DOPA to 3-OMD which may compete for CNS uptake
Used in combo with L-DOPA
Inhibits activity of COMT
Maximizes the bioavailability of L-DOPA to go into brain
Selegiline
Irreversible inhibitor of MAO-B in the striatum
Striatal MAO-B metabolizes DA
Inhibits oxidation of DA to DOPAC (increase DA levels in striatum
Dopamine Receptor Agonists
Directly activate DA receptors (bromocriptine, pramipexole)
Can be used in combo with L-DOPA/carbidopa
Act at post synaptic DA receptors
Activation of specific DA receptors may limit adverse effects of these drugs
Antimuscarinic Drugs
Block striatal muscarinic receptors (benztropine)
Not as effective as L-DOPA/carbidopa treatment
Efficient in control of tremors
Often used in combo therapy
Alleviate extrapyramidal effects caused by older anti-psychotic drugs
Amantadine
3 proposed mechanisms
Often used with L-DOPA/carbidopa therapy
Also an anti-viral drug
Used in patients who dont respond well to L-DOPA
Proposed mechanisms of action: Inhibits DA re-uptake, facilitate pre-synaptic DA release, antagonise NMDA receptors
Bromocriptinie and pramipexole
DA agonists
Selegiline
MAO inhibitors
Entacapone, tolcapone
COMT inhibitors
Benztropine
Muscarinic Antagonists